|
Trillium® Biosurface**
Triple Endothelial-like Action for Biocompatibility
Trillium® Biosurface provides endothelial-like benefits for routine use during cardiopulmonary bypass procedures.
Heparin
- Non-leaching heparin molecules are covalently bonded into the surface to provide anticoagulant and additional beneficial effects as heparan sulfate does in the natural endothelium.
Negative charge
- Sulphate and sulfonate groups are incorporated into the Trillium® functional layer to mimic the negative charge of vascular endothelium.
- Research demonstrates that negatively-charged sulphonated polymers:
- Repel the negatively-charged platelets18,19,20
- Inhibit thrombin by binding to antithrombin in a heparin-like manner21,22,23
- May impair additional processes required for thrombus formation24,25
- Heparin in Trillium® Biosurface is naturally negatively charged.
Hydrophilicity
- Polyethylene oxide (PEO) polymer is extremely hydrophilic along its entire chain, creating an "insulating" water layer structure between the blood and artificial surface to resist cell adhesion and protein deposition.
- PEO-water interface has very low free energy and therefore a low driving force for protein adsorption or platelet adhesion.26,27
- PEO chains are in continuous motion, due to their flexible molecular structure. The dynamic hydrated surface created by PEO chains is believed to repel proteins and platelets.28,29
- Hydrophilic priming layer is strongly bonded to the artificial surface.

Trillium® coated
|

Uncoated
|
Scanning electron micrographs of oxygenator fiber surfaces after one hour of in vitro circulation in a closed system using heparinized, diluted human blood. (100X magnification) |
Trillium® Biosurface peer-reviewed published clinical and scientific findings:*
- Decreased likelihood to require blood products30
- Platelet count preservation31,32,33,34,35
- Affords the same protective effects on circulating platelet count drops as adding albumin to the prime32
- Less platelet activation34
- Less granulocyte activation34
- Less complement activation after protamine administration33
- Fewer circuit clots and no renal emboli35
* Select published articles
** Technology licensed under agreement from BioInteractions, Limited, United Kingdom.
Ask your Medtronic Representative today how T2T™ can benefit your patients.
|